73 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
26
Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
Institute of Materia Medica
18
Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists.
Jiangxi University of Traditional Chinese Medicine
47
Design and Synthesis of 2-Alkylpyrimidine-4,6-diol and 6-Alkylpyridine-2,4-diol as Potent GPR84 Agonists.
East China Normal University
22
Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
Taisho Pharmaceutical
7
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
Sanofi-Aventis Deutschland
12
Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists.
Merck Research Laboratory
19
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.
Merck Research Laboratories
39
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Arena Pharmaceuticals
22
Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
AstraZeneca
11
Synthesis and biological evaluation of thienopyrimidine derivatives as GPR119 agonists.
Korea Research Institute of Chemical Technology
37
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
Arena Pharmaceuticals
31
Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.
Genomics Institute of The Novartis Research Foundation
36
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Departments of Discovery Chemistry, Metabolic Diseases, Lead Evaluation, Computer-Assisted Drug Design, Discovery Toxicology, Exploratory Clinical and Translational Research, and Pharmaceutical Candi
22
Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
Bristol Myers Squibb
42
Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Genomics Institute of The Novartis Research Foundation
48
Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
Amgen
26
Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists.
Takeda Pharmaceutical
21
Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Amgen
31
Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
Amgen
16
Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.
AstraZeneca
19
Synthesis and biological evaluation of novel 2,4-disubstituted quinazoline analogues as GPR119 agonists.
Kangwon National University
3
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
Hebrew University of Jerusalem
7
Synthesis and biological evaluation of 5-nitropyrimidine analogs with azabicyclic substituents as GPR119 agonists.
College of Pharmacy of Kangwon National University
14
Modulators of the GPR119 Receptor for the Treatment of Metabolic Syndrome.
Dart Neuroscience
37
Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119.
Pfizer
9
From partial to full agonism: identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor.
Pfizer
49
Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
AstraZeneca
14
GPR119 Modulators for the Treatment of Diabetes, Obesity, and Related Diseases: Patent Highlight.
TBA
52
Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Glaxosmithkline
4
Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry.
Boehringer Ingelheim Pharma
26
Synthesis and SAR studies of bicyclic amine series GPR119 agonists.
Sanwa Kagaku Kenkyusho
2
Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
Astellas Pharma
31
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Arena Pharmaceuticals
32
Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.
Arena Pharmaceuticals
5
Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist response.
Pfizer
16
Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor.
Pfizer
28
Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Arena Pharmaceuticals
36
Current anti-diabetic agents and their molecular targets: A review.
University of Kwazulu-Natal
13
Research progress of indole compounds with potential antidiabetic activity.
Xi'An Jiaotong University
20
Pyrazolotriazines: Biological activities, synthetic strategies and recent developments.
Mazandaran University of Medical Sciences
83
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
21
Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
Takeda Pharmaceutical
17
Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
M. S. University of Baroda
21
Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
Takeda Pharmaceutical
21
The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Chinese Academy of Medical Sciences&Peking Union Medical College
10
Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
Sichuan University
15
One-pot synthesis of novel tert-butyl-4-substituted phenyl-1H-1,2,3-triazolo piperazine/piperidine carboxylates, potential GPR119 agonists.
Koneru Lakshmaiah Education Foundation
19
Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
Japan Tobacco
6
Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders with GPR119 Agonists.
Therachem Research Medilab
3
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
University of Florida
16
Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.
Japan Tobacco
19
Discovery of novel spiro[chromane-2,4'-piperidine] derivatives as potent and orally bioavailable G-protein-coupled receptor 119 agonists.
Kowa
42
Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
Chinese Academy of Sciences
18
Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.
Jiangxi University of Traditional Chinese Medicine
28
Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.
Taisho Pharmaceutical
17
Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
Japan Tobacco
12
Synthesis and biological evaluation of thiazole derivatives as GPR119 agonists.
Sogang University
18
Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.
Merck
16
Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists.
Korea Research Institute of Chemical Technology
28
Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.
Taisho Pharmaceutical
19
Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
Kowa
14
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
Jiangxi University of Traditional Chinese Medicine
187
Compound of a reverse-turn mimetic and a production method and use therefor
Jw Pharmaceutical